Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia  

) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The study is divided into the Screening

cancer
erythropoietin
epoetin alfa
vasectomy
  • 16800 views
  • 22 Aug, 2022
  • 7 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US  

luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions.   The

cancer
erythropoietin
epoetin alfa
vasectomy
  • 54541 views
  • 22 Aug, 2022
  • 9 locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. &nbsp

epoetin alfa
  • 23120 views
  • 22 Aug, 2022
  • 10 locations
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients (EPO-TRAUMA)

The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing mortality and

  • 214 views
  • 04 Oct, 2022
  • 21 locations
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

This is an open-label, randomized, multicenter, phase III study Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO Alfa 60000 UI/week for at least 12 weeks: Either at diagnosis Or at the Hb threshold chosen for RBC transfusions (must be < 9g/dl)

  • 0 views
  • 27 Jan, 2021
  • 39 locations